Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey.

@article{Kamat2009ImpactON,
  title={Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey.},
  author={Siddhesh A. Kamat and Krithika S Rajagopalan and Judith J Stephenson and Sonalee S Agarwal},
  journal={The patient},
  year={2009},
  volume={2 2},
  pages={105-12}
}
OBJECTIVE : To assess multiple sclerosis (MS) patients' experience with natalizumab (TYSABRI, Biogen Idec, Inc. and Elan Pharmaceuticals, Inc.) in a clinical practice setting. METHODS : MS patients who were enrolled in the TOUCH (TYSABRI Outreach Unified Commitment to Health) prescribing program and who had received their third natalizumab infusion participated in this study. Patient-reported measures included an overall quality-of-life (QOL) assessment, an adapted version of the Multiple… CONTINUE READING